The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis

Eryol, Namık Kemal; Doğan, Ali; Özdoğru, İbrahіm; İnanç, Mehmet Tuğrul; Kaya, Mehmet; Kalay, Nihat

doi:10.1007/s10554-006-9174-8

Cited by 20 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical, echocardiographic and laboratory findings in Table 1 were evaluated and univariable predictors of AF were determined. We employed an epidemiological approach and factors that have been shown to be multivariable predictors of AF in the previous studies [1,[12][13][14] or P \ 0.15 with univariable analysis in Table 1 have been accepted as potential predictors. Therefore, smoking, age, functional capacity, mitral valve area, ejection fraction, left atrial diameter, and NT-proBNP, HsCRP and CA-125 levels have been entered into a multivariable logistic regression analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis

Özaydın

Türker

Varol

et al. 2010

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

The aim of this study was to evaluate the factors associated with the development of atrial fibrillation (AF) in patients with rheumatic mitral stenosis (MS). A total of 146 consecutive patients with rheumatic MS were screened. They were accepted to be in AF group and sinus rhythm group according to their rhythm in the baseline ECG. After screening, 38 patients were excluded due to hyperthyroidism (n = 13), chronic obstructive pulmonary disease (n = 22), malignancy (n = 2) and rheumatoid arthritis (n = 1). Therefore, remaining 108 patients, 74 of whom in sinus rhythm (MS-SR) and 34 of whom in AF (MS-AF) constituted study population. Fourty age- and gender-matched patients constituted control group. Factors associated with development of AF in multivariable analysis included High sensitivity C reactive protein (P = 0.005; odds ratio, 3.44; 95% confidence interval, 1.44-8.22), N-terminal of brain natriuretic peptide precursor (P < 0.0001; odds ratio, 1.03; 95% confidence interval, 1.02-1.06) and left atrial diameter (P < 0.0001; odds ratio, 1.68; 95% confidence interval, 1.32-2.14). Present study suggests that High sensitivity C reactive protein, N-terminal of brain natriuretic peptide precursor and left atrial diameter are associated with development AF in patients with MS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, serum levels of Brain natriuretic peptide (BNP), a marker of left ventricular enddiastolic pressure and Carbohydrate Antigen 125 (CA-125), a marker of venous congestion and activation of peritoneal mesothelium have been shown to be increased in patients with MS [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis

Özaydın

Türker

Varol

et al. 2010

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

show abstract

“…Interestingly, similar to our observation, they showed that those with atrial fibrillation had significantly higher NT-pro-BNP levels compared to those with sinus rhythm. In the same way, Eryol et al [12] indicated that NT-pro-BNP level in the group with severe mitral stenosis was considerably higher than that in the mild mitral stenosis and, in fact, when patients were taken together, as the area of the mitral valve decreased, the level of BNP underwent a corresponding increase. As shown by Iltumur et al [13], NT-pro-BNP levels demonstrated a significantly greater increase in severe MS than in moderate MS; in their study, there was a positive correlation with pulmonary artery pressure and a negative correlation with mitral valve area.…”

Section: Discussionmentioning

confidence: 85%

The change in NT-pro-BNP and post-PTMC echocardiography parameters in patients with mitral stenosis. A pilot study

Safi

Bayat

Ahmadi

et al. 2017

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Background. The change in the level of NT-pro-BNP (N-terminal-pro-Brain Natriuretic Peptide) is now considered as a reflection of the hemodynamic alterations and its circulatory reductions reported early after successful PTMC (percutaneous transvenous mitral commissurotomy). The present study aims to assess the change in the level of NT-pro BNP following PTMC in patients with mitral stenosis and also to determine the association between circulatory NT-pro-BNP reduction and post-PTMC echocardiography parameters. Methods. Twenty five symptomatic consecutive patients with severe MS undergoing elective PTMC were prospectively enrolled. All patients underwent echocardiography before and also 24 to 48 hours after PTMC. Peripheral blood samples were taken for measurement of NT-pro-BNP before as well as 24 to 48 hours after PTMC. The patients were also classified in group with normal sinus rhythm or having atrial fibrillation (AF) based on their 12-lead electrocardiogram. Results. It was shown a significant decrease in the parameters of PPG (Peak Pressure Gradient), MPG (Mean Pressure Gradient), PHT (Pressure Half Time), PAP (Pulmonary Arterial Pressure), LAV (Left Atrial Volume), and also a significant increase in MVA (Mitral Valve Area) RVS (Right Ventricular S velocity), and strains of lateral, septal, inferior and anterior walls of LA following PTMC. The mean LVEF remained unchanged after PTMC. The mean NT-pro-BNP before PTMC was 309.20 ± 17.97 pg/lit that significantly diminished after PTMC to 235.72 ± 22.46 pg/lit (p = 0.009). Among all echocardiography parameters, only MPG was positively associated with the change in NT-pro-BNP after PTMC. Comparing the change in echocardiography indices between the patients with normal rhythm and those with AF, lower change in PAP was shown in the group with AF. However, more change in the level of NT-pro-BNP after PTMC was shown in the patients with AF compared to those without this arrhythmia. Conclusion. PTMC procedure leads to reduce the level of NT-pro-BNP. The change in NT-pro-BNP is an indicator for change in MS severity indicated by decreasing MPG parameter. Lower change in PAP as well as higher change in NT-pro-BNP is predicted following PTMC in the group with AF compared to those with normal sinus rhythm.

show abstract

“…All studies concerning serum levels of BNP and NT-proBNP in mitral stenosis (MS) report a marked increase in the levels of these peptides in MS. (21)(22)(23) There are different reasons for this increase. Many of these patients are in atrial fi brillation (AF), which is known to be associated with increased levels.…”

Section: Mitral Stenosis (Ms)mentioning

confidence: 99%

Serum brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) in heart valve disease

Moolman

Preez

Rossouw

2017

SAHJ

View full text Add to dashboard Cite

Serum levels of natriuretic peptides (BNP and NT-proBNP) are known to increase in cardiac failure, and aid in the diagnosis and management of such patients. BNP and NT-proBNP also increase in patients with heart valve lesions, and may contribute to the assessment and management of these patients. There appears to be a general trend towards higher BNP values in more severe heart valve lesions, but the exact implication of a raised BNP or NTproBNP appears to be different for each specifi c valve lesion. In aortic valve stenosis increased levels of BNP/NT-proBNP correlate with the degree of stenosis, symptoms and prognosis. In addition, the increased natriuretic peptide levels seem to refl ect left ventricular dysfunction, as high levels predict poor long-term outcomes in conservatively treated patients as well as post-operative death and poor functional recovery in those who survive the valve replacement procedure. In mitral regurgitation natriuretic peptide levels correlate with the degree of valvular regurgitation, and seem to refl ect subclinical left ventricular dysfunction. Serum natriuretic peptide levels are elevated in patients with mitral stenosis, and correlate with the degree of valvular stenosis and increased pulmonary pressure. Serum levels of natriuretic peptides are elevated in other heart valve lesions, such as aortic valve regurgitation, as well as different forms of mixed valvular disease, but very little is ABSTRACT BNP AND NT-proBNP IN HEART VALVE DISEASE known about the relationship between the serum levels of natriuretic peptides and the latter valve lesions. The practical application of our knowledge concerning serum natriuretic peptides and heart valve disease is limited at this stage, and no specifi c cut-off values to guide patient management have been incorporated into any offi cial guidelines as yet. This review aims to summarise current knowledge on serum BNP and NT-proBNP levels in patients with heart valve disease. The impact of this information on current clinical decision making in patients with different heart valve lesions, as well as evolving concepts concerning its potential future use, will be discussed.

show abstract

The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis

Cited by 20 publications

References 35 publications

Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis

Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis

The change in NT-pro-BNP and post-PTMC echocardiography parameters in patients with mitral stenosis. A pilot study

Serum brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) in heart valve disease

Contact Info

Product

Resources

About